Aug. 6, 2025

The ACR® Center for Research and Innovation (CRI®) served as the imaging contract research organization for the DOORwaY90 clinical trial that contributed to FDA approval of Sirtex SIR-Spheres technology for liver cancer treatment.

CRI’s management of image and data collection, quality control, and central review of 600 CT/MRI scans from 65 subjects across 12 sites using five expert reviewers was critical to the success of the trial.

Interim analysis of the DOORwaY90 trial revealed that 98.5% of patients had the Best Overall Response Rate through nine months and 100% of all evaluable patients were able to demonstrate local tumor control.

Related ACR News

  • CMS Updates ICD-10 Codes for Radiology NCDs

    Change Request 14194 details ICD-10 coding revisions for mammograms, PET for oncologic conditions and percutaneous image-guided breast biopsy.

    Read more
  • House Spending Bill Maintains NIH Funding Levels

    The House FY2026 spending bill maintains NIH funding at $48B, rejecting proposed cuts; ACR continues advocacy for medical research as a national priority.

    Read more
  • Feds Propose Revising Small Business Size Standards

    The SBA released a proposed rule to revise the monetary-based small business size standards for 263 industries, including diagnostic imaging centers.

    Read more